ANDRX-Reaffirm Outperform Recommendation-Gruntal Research Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANDRX-Reaffirm Outperform Recommendation-Gruntal Research

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PAUL ROBERT ST. ONGE who wrote (6)	11/13/1996 12:54:00 AM
From: James Silverman	of 23

Paul, I've received the ADRX investment packet. Going to have Biovail send me theirs tomorrow. Just want to see how far they are along with products ADRX is working on. I'm trying to gauge how long the exclusivity period for ADRX will be for Cardizem CD whenever it is approved. One item I noticed which is significant. I had previously thought Watson and ADRX had JV rights to Cardizem CD, Dilacor XR, that is not the case. ADRX has these two initial drugs exclusively as of now. This is very positive as the profits on this are theirs to keep.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next